Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

What Does Off-label Prescribing Really Mean?

What Does Off-label Prescribing Really Mean? EDITORIAL HE ISSUE OF OFF-LABEL PRESCRIBING IS A off-label prescribing accounts for 1 in 9 of all prescrip- loaded subject. When one scratches the tions and that much of this off-label use is for neuro- surface, one realizes the myriad limita- genic pain-related conditions. Information on the ap- tions of such a construct related to the pro- propriateness of treatment is not known. As we know, T cess of labeling, the monitoring of appro- the off-label designation does not mean that there is in- priate prescribing, the inadequacy of evidence to match sufficient evidence for use. The more important infor- the complexities of care, and the missed opportunities mation is the utilization by strength of evidence, whereby of leveraging our information systems to better opti- there is likely inappropriate practice occurring with medi- mize medication use for the care of patients. cation use for which there is insufficient evidence. How- ever, we cannot really judge the scope or severity of the risk of such practice without knowing the correspond- See also page 781 ing clinical outcomes associated with such prescribing. The real issue is that of the appropriate use of medica- Technically, off-label prescribing means the prescrib- tions, and http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

What Does Off-label Prescribing Really Mean?

JAMA Internal Medicine , Volume 172 (10) – May 28, 2012

Loading next page...
 
/lp/american-medical-association/what-does-off-label-prescribing-really-mean-aB7f9HkDJM
Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinternmed.2012.789
pmid
22507697
Publisher site
See Article on Publisher Site

Abstract

EDITORIAL HE ISSUE OF OFF-LABEL PRESCRIBING IS A off-label prescribing accounts for 1 in 9 of all prescrip- loaded subject. When one scratches the tions and that much of this off-label use is for neuro- surface, one realizes the myriad limita- genic pain-related conditions. Information on the ap- tions of such a construct related to the pro- propriateness of treatment is not known. As we know, T cess of labeling, the monitoring of appro- the off-label designation does not mean that there is in- priate prescribing, the inadequacy of evidence to match sufficient evidence for use. The more important infor- the complexities of care, and the missed opportunities mation is the utilization by strength of evidence, whereby of leveraging our information systems to better opti- there is likely inappropriate practice occurring with medi- mize medication use for the care of patients. cation use for which there is insufficient evidence. How- ever, we cannot really judge the scope or severity of the risk of such practice without knowing the correspond- See also page 781 ing clinical outcomes associated with such prescribing. The real issue is that of the appropriate use of medica- Technically, off-label prescribing means the prescrib- tions, and

Journal

JAMA Internal MedicineAmerican Medical Association

Published: May 28, 2012

References